What Triastek does

Triastek, Inc. is a privately held Chinese pharmaceutical technology company founded in July 2015 and headquartered in Nanjing, Jiangsu, with additional offices in Shanghai and a GMP-compliant production facility in Nanjing. The company developed and commercializes the proprietary Melt Extrusion Deposition (MED®) 3D printing process, an additive manufacturing technology that continuously converts powder feedstocks into softened or molten states and deposits them layer-by-layer to produce solid oral dosage forms with engineered 3D geometric structures. MED® operates across a 25–250°C temperature range, supports more than 200 pharmaceutical excipients and 1,000+ compositions, and integrates Process Analytical Technology (PAT) for real-time, per-tablet quality control. The platform is complemented by a family of five specialized 3D Microstructure delivery technology platforms (3DμS®-IT, -MR, -GR, -SE, -OM) and two hybrid processes (MED&MIM for gastric retention, MED&SSE for peptides), as well as the 3DFbD® digital formulation-by-design methodology.

The company operates a dual business model. In its Product Partnership model, Triastek internally develops proprietary 3D-printed drug candidates (T19, T20, T20G, T21, T24, T25, T26, D23) through FDA 505(b)(1)/(b)(2) and NMPA pathways and out-licenses global commercialization rights for upfront fees, development milestones, and royalties. In its Technology Platform Partnership model, it provides MED® platform access, research collaboration, and co-development services to global pharmaceutical companies; named partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck KGaA (MilliporeSigma), Siemens, and Sperogenix. Revenue is generated through research fees, milestone payments, technology access fees, and licensing royalties. The company holds 152 patent applications and 117 granted patents across 12 territories, representing more than 20% of global 3D printing pharmaceutical patent applications, and was the first Chinese pharmaceutical company accepted into the US FDA Emerging Technology Program.

Name

Triastek

Legal name

Triastek, Inc.

Website

https://triastek.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Triastek is a Chinese pharmaceutical 3D printing company that develops the proprietary MED® platform and five 3DμS® delivery technology platforms to create programmable oral drug products, serving global pharma companies through licensing, co-development, and technology partnerships.

Ownership category

akta.pro rank

Product category

3D Printed Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• 3D printed pharmaceuticals
• Pharmaceutical drug delivery
• Controlled release formulations
• Melt extrusion deposition
• Continuous pharmaceutical manufacturing

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Product License-out Partnerships: Triastek develops proprietary 3D printed drug candidates through clinical development and out-licenses global commercialization rights to pharmaceutical partners. Revenue generated through upfront payments, milestone payments, and royalties on net sales.
2. Technology Platform Services: Providing MED® technology platform access to global pharmaceutical companies via research collaboration, platform co-development, and technology licensing. Partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck/MilliporeSigma, and Sperogenix. Generates revenue through research fees, milestone payments, and technology access fees.
3. Product Co-development: Co-developing 3D printed pharmaceutical products with pharmaceutical partners using 505(b)(1) and 505(b)(2) pathways, sharing development costs and future revenues.
4. Licensing Royalties from IP Portfolio: Triastek holds 152 patent applications and 117 granted patents across 12 territories, constituting over 20% of global 3D printing pharmaceutical patent applications. IP licensing generates ongoing revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Triastek develops and manufactures proprietary 3D-printed pharmaceutical drug products using its MED® (Melt Extrusion Deposition) additive manufacturing technology, which produces solid oral dosage forms with programmable 3D geometric structures enabling precise control over drug release timing, location, and rate. The company commercializes via two B2B models: (1) Product License-out Partnerships, in which Triastek's IND-cleared drug candidates (D23, T20G, T24, T25, T26) are out-licensed to global pharma partners for commercialization, and (2) Technology Platform Partnerships, providing MED® platform access and co-development services to pharmaceutical companies like Eli Lilly, Boehringer Ingelheim, BioNTech, and Merck KGaA. Manufacturing is performed at a GMP-compliant 3D printing pharmaceutical continuous production line in Nanjing with 75 million tablets annual capacity.

Product overview

Triastek is a pharmaceutical technology company offering a platform-based approach centered on its proprietary MED® (Melt Extrusion Deposition) 3D printing technology. The core platform is complemented by five specialized 3D microstructure delivery technology platforms: 3DμS®-IT (intestine targeting), 3DμS®-MR (modified release), 3DμS®-GR (gastric retention), 3DμS®-SE (solubility enhancement), and 3DμS®-OM (oral macromolecules). The company also provides the 3DFbD® digital formulation development tool. Triastek's technology enables programmable precise control of drug release timing, location, and rate. The company operates two complementary business models: developing proprietary drug products (T19, T20, T20G, T21, T24, T25, T26, D23) internally for licensing out, and offering technology platform partnerships to global pharmaceutical companies. The manufacturing processes include MED® (standard), MED&MIM (melt extrusion with micro-injection molding for gastric retention), and MED&SSE (melt extrusion with semi-solid extrusion for peptides and macromolecules).

Differentiator

Problem solved

Functional benefit

Brands

• MED®: Melt Extrusion Deposition - Triastek's proprietary 3D printing pharmaceutical process that transforms delivery, development, and production of medicines through digital product development and continuous manufacturing.
• 3DμS®
• 3DFbD®

Products and services

• MED® (Melt Extrusion Deposition) 3D Printing Process Triastek's proprietary additive manufacturing technology platform that continuously converts powder feedstocks into softened/molten states followed by precise layer-by-layer deposition to produce solid dosage forms with designed 3D geometric structures. Operates at 25°C–250°C, handles 200+ pharmaceutical excipients and 1000+ compositions, uses fully automated continuous manufacturing with real-time PAT feedback control, and is sold/licensed to pharmaceutical partners via the Technology Platform Partnership model.
• T19 (Budesonide Delayed-Release Tablet) Triastek's first 3D printed drug product, a chronotherapeutic budesonide delayed-release tablet for rheumatoid arthritis. Taken at bedtime with delayed release for blood concentration peaks in early morning hours when RA symptoms are most acute. Developed using MED® 3D printing and the 3DμS®-MR modified release platform.
• T20 (Apixaban Cardiovascular Product) 3D printed apixaban product for cardiovascular and clotting disorders developed using the 3DFbD® digital formulation method as a once-daily formulation. The second Triastek product to receive FDA IND clearance.
• T20G (Apixaban Gastroretentive Extended-Release Capsule) 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product for stroke prevention in atrial fibrillation (NVAF), DVT, PE, and VTE. Uses the MED&MIM process with 3DμS®-GR platform for once-daily dosing versus twice-daily for the reference listed drug.
• T21 (Colon-Targeted Tablet) Colon-targeted 3D printed drug product for the treatment of ulcerative colitis. Uses an enteric layer and delay layer protecting the drug core for precise delivery to the colon, with X-ray imaging verification of colon targeting achieved in first-in-human study.
• T24 (Ramelteon Dual-Release Tablet) Dual-release tablet for insomnia providing single dosing with dual precise timed-release addressing both sleep initiation and sleep maintenance difficulties. Built on the 3DμS®-MR modified release platform using MED® 3D printing.
• T25 (Octreotide Acetate Tablet) Oral peptide product for maintenance treatment of adult patients with acromegaly. First oral peptide candidate to enter clinical development. Uses the MED&SSE process and 3DμS®-OM dual-chamber delivery system to protect octreotide from gastric degradation and enable precise delivery to intended absorption sites.
• T26 (Itraconazole Tablet) 3D printed solubility-enhancing antifungal product for treatment of mycoses. Built on the 3DμS®-SE delivery system combining amorphous solid dispersion with precision-engineered honeycomb microstructures to improve bioavailability of poorly soluble itraconazole, eliminating non-environmentally friendly organic solvents like dichloromethane.
• D23 (Budesonide Ileum Targeted Tablets) Ileum-targeted budesonide delayed-release tablet for the treatment of IgA nephropathy (IgAN). Uses MED® 3D printing and the 3DμS®-IT intestine targeting platform to precisely deliver budesonide to Peyer's lymph nodes in the ileum, reducing patient medication burden from 4 capsules of the originator to a single tablet design.
• MED® Technology Platform Partnership Service Technology platform service providing pharmaceutical companies access to Triastek's MED® 3D printing process, 3DFbD® digital formulation methodology, and 3DμS® delivery technology platforms via research collaboration, co-development, and technology licensing. Named partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck KGaA, Siemens, and Sperogenix.
• Product License-out Partnership Service Licensing service through which Triastek out-licenses its proprietary IND-cleared 3D printed drug candidates to global pharmaceutical companies for commercialization. Triastek retains IP rights; partners obtain commercialization rights in exchange for upfront fees, milestone payments, and royalties on net sales. Active licensed products include D23, T24, T20G, T25, and T26.

Quantifiable outcome

• T19 achieves blood concentration peak in early morning hours matching circadian rhythm of rheumatoid arthritis symptoms, improving symptom relief vs. standard formulations.
• +6 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Six partnerships are on record, tiered major and moderate.

• BioNTech SEmajorStrategic or Co-development Partner · 23 July 2024Research collaboration and platform technology license agreement to develop RNA therapeutics for oral delivery based on 3D printing technology. Aims to provide groundbreaking therapies to address unmet medical needs in easy-to-administer oral formulations. First announced July 2024.
• Boehringer Ingelheim ChinamajorStrategic or Co-development Partner · 17 March 2023Collaboration to explore application of Triastek's MED® 3D printing technology in accelerating development of dosage forms for new chemical entities (NCE). Triastek deploys MED® technology to create multiple prototypes exploring different dose designs and drug release behaviors at speed, accelerating R&D cycles and increasing product development success rates. Boehringer Ingelheim showcased Triastek's 3D printed drug development prototype at CIIE 2023.
• Eli Lilly and CompanymajorStrategic or Co-development Partner · 13 July 2022Research collaboration to leverage 3D printing technology for precisely targeted and programmed release of drugs in specific regions of the GI tract. Project focuses on intestinal targeted release, studying excipient properties, process parameters for drug stability, and unique 3D structure dosage form designs for programmed release to improve bioavailability of orally administered drugs. Facilitated by Lilly China Innovation & Partnerships.
• Siemens Ltd., ChinamajorTechnology or Integration · 3 March 2022Strategic collaboration for digital transformation of the pharmaceutical industry. Combines Triastek's 3D printing and digital pharmaceutical technologies with Siemens' global leadership in automation and digitization. Collaboration areas include continuous manufacturing, paperless production, real-time product release, equipment and facility maintenance, digital twin technologies, and establishment of an intelligent pharmaceutical manufacturing center. Deepening strategic cooperation agreement signed at CIIE 2023.
• Merck KGaA (MilliporeSigma / SAFC Raw Materials)moderateStrategic or Co-development PartnerJoint research project to demonstrate applicability of PVA solubility enhancement platform (Parteck® MXP excipient) for 3D printing using MED® technology. Focused on continuous printing of poorly soluble drugs using amorphous solid dispersions. Synergies between Triastek's MED® technology and MilliporeSigma's PVA solubility excipient demonstrated for fine-tuning release kinetics with designed structures.
• SperogenixmoderateStrategic or Co-development PartnerStrategic partnership for innovative pharmaceutical product development using MED® 3D printing technology. Mentioned among Triastek's established strategic partnerships with global pharmaceutical companies including Eli Lilly, Merck, Boehringer Ingelheim, and Siemens.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Aprecia Pharmaceuticals: Aprecia is the only FDA-approved 3D printed pharmaceutical company (Spritam/levetiracetam, approved 2015). Directly comparable as a pioneer in 3D printing pharmaceuticals with proprietary binder jetting technology. Most established competitor in Triastek's category.
• FabRx: UK-based 3D printing pharmaceutical company founded in 2018, specializing in personalized medicines and pharmaceutical 3D printing technologies. Directly comparable as a specialized 3D pharma company pursuing clinical and commercial applications of additive manufacturing for drug products.

Emerging players

• Laxxon Medical: Laxxon Medical is a US/Germany-based pharmaceutical technology company developing 3D printed pharmaceuticals with a focus on oral dosage forms. Comparable as an emerging 3D pharma player pursuing similar application areas (modified release, solubility enhancement) using additive manufacturing.
• Craft Health: Craft Health is a Singapore/US-based 3D printed pharmaceutical company developing personalized medicines and 3D printed drug products. Comparable as an emerging 3D pharma player in the additive manufacturing pharmaceutical space.
• Extend Biosciences: Extend Biosciences is a US-based biotech developing delivery technologies for peptides and proteins, including oral and injectable sustained-release formulations. Comparable as an emerging player focused on challenging formulation/delivery problems similar to Triastek's 3DμS®-OM platform.

Broad incumbents

• Merck KGaA (MilliporeSigma): Global pharmaceutical and life sciences company that has partnered with Triastek on solubility enhancement excipients (Parteck MXP) and has its own 3D printing pharmaceutical initiatives. Comparable as a broad incumbent with overlapping 3D pharma interests and as an existing Triastek partner.
• Eli Lilly: Global pharmaceutical MNC that partnered with Triastek on intestinal-targeted 3D printed drug delivery. Comparable as a broad incumbent exploring 3D printing for oral drug delivery and an active Triastek partner.
• BioNTech: Global biotechnology company that entered a research collaboration and platform technology license with Triastek for oral RNA therapeutics. Comparable as a leading biotech exploring 3D printed oral biologics delivery and an active Triastek partner.
• Boehringer Ingelheim: Global pharmaceutical company collaborating with Triastek on 3D printing for new chemical entity dosage form development. Comparable as a broad incumbent exploring 3D pharma applications and an active Triastek partner.
• Siemens Healthineers: Global health technology and automation company partnering with Triastek on digital pharmaceutical manufacturing. Comparable as a broad incumbent collaborating on continuous manufacturing automation and digital transformation in pharmaceutical 3D printing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/triastek-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triastek